Page 305 - ebook HCC

EASL HCC SUMMITHCC SUMMIT
GENEVA, SWITZERLANDA, SWITZERLAND
PROGRAMME AND ABSTRACTSAND ABSTRACTS
303
302
302 PROGRAMME GENEV EASL 303
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C69
HCC TREATMENT AND PVT

Francesca Romana Ponziani , Maria Assunta Zocco , Matteo Garcovich ,
1
2
2
Valentina Cesario , Francesca D’Aversa , Teresa Antonella Di Rienzo , Patient’s characteristic Mean±SD/Frequency
2
2
2
Anna Maria De Gaetano , Emanuele Rinninella , Davide Roccarina , AGE (years) 64±9 (35-87)
2
2
2
Maria Chiara Campanale , Federico Barbaro , Annalisa Tortora , Gianluigi Caracciolo , SEX 167M/42F
2
2
2
2
Giovanni Gigante , Gianluca Ianiro, Massimo Siciliano, Brigida Eleonora Annicchiarico, Liver disease Chronic hepatopathy 23/209 (11%)/cirrhosis 176/209 (84.2%)/none 9/209
2
Alessandro Milani, Giovanni Gasbarrini, Salvatore Agnes, Alfonso Wolfango Avolio, (4.3%)
Antonio Grieco, Gennaro Nuzzo, Felice Giuliante, Gian Ludovico Rapaccini, Etiology of liver disease Viral 143/209 (68.4%)/alcoholic 30/209 (14.4%)/viral+alcoholic 10/209 (4.8%)/
Maurizio Pompili, Antonio Gasbarrini and HEPATOCAT other 17/209 (17.1%)/none 5/209 (2.4%)
multidisciplinary group for the treatment of HCC BCLC A: 94/186 (50.5%) B: 39/186 (20.9%) C: 54/186 (29%)
2
1 Internal Medicine and Gastroenterology, A Gemelli Hospital, Rome, Italy D: 19/186 (10.2%) 23 no cirrhosis
Milano criteria “in” 108/205 (98.1%)
Child-Pugh A: 113/186 (60.7%) B: 32/186 (17.2%) C: 5/186 (2.6%) 23 no cirrhosis
Corresponding author’s e-mail: francesca.ponziani@yahoo.it
MELD 11±0,6 (6-26)
PVT No 151/209 (72.2%)/ non-malignant 12/209 (5.7%)/ malignant 46/209 (22%)
Caval invasion 6/209 (2.8%)
Introduction: Portal vein thrombosis (PVT) is a relatively common complication in Metastasis 9/209 (4.3%)
cirrhotics (prevalence 0.6%>16%, 6.5% in patients with hepatocellular carcinoma-HCC).
To date, there are no data concerning the impact of PVT, both malignant or non-malignant,
on HCC treatment outcome. Results: 96/209 patients enrolled (45.9%) experienced TF, and 77 (36.8%) TR. mPVT
was associated to TF (p=0.004; chi-squared 11.262) and to TR (p=0.042; chi-squared
Aims: To retrospectively investigate the impact of malignant (mPVT) or non-malignant 6.362). Viral or alcoholic liver disease etiology (p=0.044; chi-squared 18.742) were the
PVT (nmPVT) on HCC treatment outcome and to evaluate factors associated with PVT most common among patients with mPVT or nmPVT, mPVT occurred in HCC outside
development. Milan criteria while nmPVT in HCC within Milan criteria (p=0.001; chi-squared 14.365),
finally caval invasion was frequent in mPVT patients but non in nmPVT ones (p=0.008;
Methodology: 209 cirrhotic patients with HCC were selected from the database of the chi-squared 9.672); however only HCC outside Milan criteria (OR 0.743 p=0.017;
HEPATOCAT multidisciplinary group for the treatment of HCC. Patients’ characteristics 95%CI -0.538,-0.54) and caval invasion (OR 2.172 p=0.039; 95%CI 0.040,1.512) were
CLINICAL POSTER ABSTRACTS Treatment outcome was evaluated according to m-RECIST criteria as absence of Conclusion: mPVT has a negative impact on HCC treatment, since it is associated with CLINICAL POSTER ABSTRACTS
were shown in table 1.
independently associated with PVT occurrence.
complete response to single or repeated treatment (treatment failure, TF; tumor
a higher risk of TF or TR. PVT seems more common in patients with HCC outside Milan
criteria and caval invasion; in particular, mPVT is more frequent in patients with advanced
recurrence after complete response, TR). mPVT or nmPVT was diagnosed by contrast
BCLC stage.
enhanced CT or MRI.